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Abstract Mikulicz’s disease (MD) has been included within
the diagnosis of primary Sjögren’s syndrome (SS), but it
represents a unique condition involving persistent enlarge-
ment of the lacrimal and salivary glands characterized by
few autoimmune reactions and good responsiveness to glu-
cocorticoids, leading to the recovery of gland function.
Mikulicz’s disease was recently reported to be associated
with elevated immunoglobulin G4 (IgG4) concentrations in
the serum and prominent inﬁltration of plasmacytes ex-
pressing IgG4 into the lacrimal and salivary glands. The
following features were used for diagnosis: (1) visual
conﬁrmation of symmetrical and persistent swelling in more
than two lacrimal and major salivary glands; (2) prominent
mononuclear cell inﬁltration of lacrimal and salivary glands;
and (3) exclusion of other diseases that present with glandu-
lar swelling, such as sarcoidosis and lymphoproliferative
disease. These features are not observed in most SS cases.
The complications of MD include autoimmune pancreatitis,
retroperitoneal ﬁbrosis, tubulointerstitial nephritis, autoim-
mune hypophysitis, and Riedel’s thyroiditis, all of which
show IgG4 involvement in their pathogenesis. Mikulicz’s
disease thus differs from SS and may be a systemic IgG4-
related plasmacytic disease.
Key words Autoimmune pancreatitis · Glucocorticoid ·
Immunoglobulin G4 · Mikulicz’s disease · Sjögren’s
syndrome
M. Yamamoto (*) · H. Takahashi · M. Ohara · C. Suzuki ·
Y. Naishiro · H. Yamamoto · Y. Shinomura
First Department of Internal Medicine, Sapporo Medical University
School of Medicine, South 1, West 16, Chuo-ku, Sapporo 060-8543,
Japan
Tel. +81-11-611-2111; Fax +81-11-611-2282
e-mail: mocha@cocoa.plala.or.jp
K. Imai
Sapporo Medical University, Sapporo, Japan
Introduction to Mikulicz’s disease
Mikulicz’s disease (MD) refers to idiopathic, bilateral, pain-
less, and symmetrical swelling of the lacrimal, parotid, and
submandibular glands. Because MD and Sjögren’s syn-
drome (SS) are histologically similar, MD has been consid-
ered as a subtype of SS. However, there are some clinical
differences between MD and typical SS. In MD, the en-
largement of lacrimal and salivary glands is persistent and
secretory dysfunction is either not detectable or slight.
Further, MD shows good responsiveness to steroids. Sero-
logically, MD patients exhibit normal or hypergamma-
globulinemia and normal or hypocomplementemia, but
lacks anti-SS-A and anti-SS-B antibodies. Recently, it has
also been conﬁrmed that MD patients show elevated serum
immunoglobulin G4 (IgG4) concentrations and inﬁltration
of plasmacytes expressing IgG4 into the lacrimal and sali-
vary glands. Thus, MD apparently differs from SS. Atten-
tion has also been paid to the pathological similarities
between MD and autoimmune pancreatitis (AIP), particu-
larly the role of IgG4, and new developments are expected
to clarify the pathogenesis of both diseases. Here, we sum-
marize the results of recent studies and provide an overview
of MD.
Historical details and the concept of Mikulicz’s
disease
In 1888, Johann von Mikulicz-Radecki reported a case that
exhibited bilateral, painless, and symmetrical swelling of
the lacrimal, parotid, and submandibular glands.
1  Napp
later reported that these symptoms presented with leuke-
mia, lymphoma, sarcoidosis, tuberculosis, and lues.
2  To
clarify this, in 1927 Schaffer linked cases with obvious dis-
eases presenting these symptoms as Mikulicz’s syndrome
and idiopathic cases as MD.
3 On the other hand, in 1933,
Sjögren analyzed 19 cases with keratoconjunctivitis sicca, 2
of which displayed swelling of the major salivary glands.
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The concept of SS was established after this report. In 1953,
Morgan and Castleman examined specimens from 18 cases
diagnosed with MD. After ﬁnding histological similarities
between MD and SS, they announced that most cases re-
ported as MD could be considered as SS.
5,6 Subsequently,
MD has been considered as a subtype of SS, and case re-
ports of MD have disappeared.
However, when we resurveyed the thesis by Morgan and
Castleman,
5 we identiﬁed several problems, such as the in-
clusion of the many cases that lack swelling of the lacrimal
glands or only show swelling of one side of the glands. This
led us to question whether these cases were actually MD.
The histological characteristics that Morgan reported as
being common among the 18 cases were as follows: (1)
degeneration and disappearance of acini due to severe
mononuclear cell inﬁltration, (2) proliferation of ductal epi-
thelial cells and duct stenosis, (3) formation of myoepithe-
lial islands, and (4) cystic dilatation of peripheral ducts.
However, it is reported that these characteristics were ob-
served not only in SS but also in persistent and destructive
pathogenesis such as sialolithiasis in the glands.
7 Thus, the
exclusion of MD from SS, which Morgan deﬁned is under
increasing scrutiny, and numerous studies on the relation-
ships between MD and SS have been undertaken in Japan.
Differences between Mikulicz’s disease and
Sjögren’s syndrome
Our classiﬁcation of Mikulicz’s disease
We based our classiﬁcation of MD on the following fea-
tures: (1) visual conﬁrmation of symmetrical and persistent
swelling in more than two lacrimal and major salivary
glands, (2) prominent mononuclear cell inﬁltration of lacri-
mal and salivary glands, and (3) exclusion of other diseases
that present with glandular swelling such as sarcoidosis and
lymphoproliferative disease.
7 The aim of this classiﬁcation is
to establish disease independence and clarify the serological
and histopathological differences between MD and SS.
8
Analyses were performed in 16 MD patients (4 men and 12
women) who consulted doctors at Sapporo Medical Univer-
sity and its related facilities between April 1997 and Octo-
ber 2005; these cases were compared with primary SS cases.
Another 16 patients in whom SS was diagnosed on the basis
of the revised Japanese criteria were also studied.
9 We de-
ﬁned cases as MD when they satisﬁed both our classiﬁcation
and the revised Japanese criteria for SS.
Clinical characteristics of Mikulicz’s disease
Our MD patients were mainly middle-aged or elderly fe-
males. The average age was 58.6 years (range 25–73 years)
with a sex ratio of approximately 3:1 in favor of females.
However, male patients predominated when reports from
other facilities were analyzed together with our data.
10 The
enlargement of the lacrimal and salivary glands in MD pa-
tients was found to be elastic, painless, and persistent (oc-
curring for more than 3 months). Half of the MD patients
did not exhibit keratoconjunctivitis sicca. With regard to
salivary gland function, secretion by these glands in MD
was normal or slightly decreased, and this improved with
steroid treatment. On the other hand, the 16 patients with
SS were all females in their forties and ﬁfties. The sex ratio
for SS is usually approximately 20:1 (female:male).
11 Our
results did not contradict the general consensus. The lacri-
mal and salivary swelling in SS presented repeatedly and
disappeared without treatment. The sicca symptoms were
severe in SS. We prescribed glucocorticoids to SS patients
for treating the swelling of the lateral submandibular gland,
but the amount of saliva did not increase. We do not expect
improvements in glandular secretion in advanced stages of
SS since SS is an autoimmune disease that irreversibly dam-
ages glands.
12 There were a few reports on the efﬁcacy of a
low dose of prednisolone on saliva production in patients
with primary SS; however, in the thesis, it was not clear how
long these cases had suffered from SS.
12,13 It was then men-
tioned that in authoritative textbooks, systemic corticoster-
oids were used for treating only severe extraglandular
diseases, including diffuse interstitial pneumonia, glomeru-
lonephritis, vasculitis, and peripheral neuropathy.
14–16 The
impact of steroids on the natural course of SS is not well
established. The clinical ﬁgures of MD are thus quite differ-
ent from those of typical SS.
Diagnostic imaging of Mikulicz’s disease
Computed tomography (CT) from the head to the neck in
MD patients revealed severe enlargement of symmetrical
lacrimal and submandibular or parotid glands. The size of
the neck lymph nodes was less than 1cm. Ultrasonography
of the enlarged glands revealed that the foci were irregular,
hypoechoic, and multilocular, while the power Doppler
method showed the presence of hypervascular masses. Sia-
lography was normal, and the “apple-tree sign,” which is
typical of SS, was not observed in MD.
Serological tests in Mikulicz’s disease
Half of the MD patients exhibited hypergammaglobuline-
mia. A few patients had antinuclear antibodies in MD, and
with the exception of one patient, did not have anti-SS-A or
anti-SS-B antibodies. On the other hand, SS patients exhib-
ited hypergammaglobulinemia and were largely positive for
anti-SS-A (69%) and anti-SS-B (31%) antibodies.
Mikulicz’s disease and IgG4
We focused on hypergammaglobulinemia, which was ob-
served in MD. Serum IgG subclasses in each group of MD
and SS (each 16 patients) were measured by nephelometry.
Mean total IgG levels were 3226.9mg/dl and 2398.1mg/dl in
MD and SS, respectively. There were no signiﬁcant differ-
ences between the groups. Serum IgG subclasses in MD337
were 1256.4mg/dl and 1111.0mg/dl for IgG1 and IgG4, re-
spectively, and those in SS were 1624.9mg/dl and 88.8mg/dl
for IgG1 and IgG4 (P < 0.05, P < 0.0001), respectively. The
IgG1/total IgG and IgG4/total IgG ratios were 41.5% and
28.6%, respectively, in MD and 73.0% (P < 0.0001) and
2.8% (P < 0.0001), respectively, in SS (Fig. 1). In healthy
controls, these ratios for each IgG subclass were as follows:
IgG1, 65%; IgG2, 25%; IgG3, 6%; and IgG4, 4%. IgG1
usually accounts for most of the total IgG.
17 Generally, the
amount of IgG4 does not vary with sex or age, and the
quantity of IgG4 as well as the IgG4/total IgG ratio tends to
remain constant.
18 Our serological analysis revealed that all
MD patients had elevated concentrations of IgG4, which
has not been observed in any other connective tissue dis-
ease, including SS, systemic lupus erythematosus, rheuma-
toid arthritis, and polymyositis.
19  Elevated serum IgG4
concentrations were very speciﬁc to MD patients.
As described above, Morgan and Castleman reported
that MD and SS were histopathologically identical.
5,6 Upon
hematoxylin–eosin staining, lacrimal or salivary gland
specimens from MD showed severe mononuclear cell inﬁl-
tration and lymphoid follicles around the ductal and acinar
cells. We were not able to identify any difference between
MD and SS using typical histopathological analyses. How-
ever, Tsubota et al. reported that the frequency of apoptosis
of lacrimal gland cells was signiﬁcantly lower in MD.
20,21 We
also observed this phenomenon in salivary glands by using
the terminal deoxynucleotidyl transferase-mediated dUTP
digoxigenin nick-end labeling (TUNEL) method.
22  This
phenomenon may be related to the reversibility of lacrimal
and salivary functions by glucocorticoid treatment. The rea-
sons apoptosis is not widely induced in MD are unclear, but
abnormalities in the Fas/Fas ligand system in lymphocytes,
acinar and ductal cells may be involved.
22
We then examined the lacrimal and salivary glands
for anti-IgG4 antibody staining since elevated concentra-
tions of IgG4 were detected in MD patients. The inﬁltration
of numerous IgG4-positive plasmacytes near acinar and
ductal cells and around lymphoid follicles was conﬁrmed in
MD;
8 however, the specimens from SS patients showed no
plasma cells with IgG4 (Fig. 2). Thus, this ﬁnding clearly
differentiates between MD and SS (Table 1). It is possible
that MD is a systemic IgG4-related plasmacytic disease be-
cause in MD, we also detected abundant IgG4-bearing
plasma cells in the stomach, colon, and kidney as well as in
lymphoid tissues such as the cervical lymph nodes and bone
marrow.
7,8
Treatment of Mikulicz’s disease
Mikulicz’s disease is mainly treated by the administration of
steroids. We initiate prednisolone at 30–40mg/day against
MD without organ failure. This leads to rapid improvement
in glandular swelling as well as in lacrimal and salivary
secretion. Prescription of glucocorticoids for 2 months led
to an increase from 6.9mm/5min to 15.7mm/5min (P  <
0.05) in Schirmer’s test (16 eyes), which reﬂects improved
lacrimal secretion, and an increase from 1.98g/2min to
3.66g/2min (P  <  0.05) in Saxon’s test (8 MD patients),
which reﬂects improved salivary secretion.
23 Glucocorticoid
administration also improved hypergammaglobulinemia. A
prescription for 2 months induced decreases in serum IgG
levels (from 4270.0mg/dl to 1440.1mg/dl; P < 0.005) in 8
MD patients. The serum IgG1 levels decreased from
1632.9mg/dl to 681.0mg/dl (P < 0.005) and those of serum
IgG4 decreased from 1556.4mg/dl to 234.7mg/dl (P  <
0
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Fig. 1. Ratio of each IgG subclass/total IgG. The IgG4/total IgG ratio
increased signiﬁcantly in Mikulicz’s disease, when compared with that
in Sjögren syndrome
Table 1. Clinical characteristics of Mikulicz’s disease and Sjögren’s syndrome
Mikulicz’s disease Sjögren’s syndrome
Age of disease onset Predominantly from 50s to 60s From 40s to 50s
Sex ratio ? (Increased prevalence of males) 20:1 in favor of females
Gland swelling Persistent Recurrent
Keratoconjunctivitis sicca None to slight Mild to severe
Dysfunction of salivary secretion None to slight Mild to severe
Response to steroid Very good No change, or sometimes good
Serum IgG Normal to very high Normal to high
Antinuclear antibody Dominance of negative cases Dominance of positive cases
Anti-SS-A/SS-B antibodies Negative Positive (70%/30%)
Ratio for serum IgG4/total IgG Severely high (30%) Normal (4%)
Glands biopsy Inﬁltration of abundant IgG4-positive No detection of IgG4-positive cells, and
plasmacytes, and lower frequency of observed apoptosis of acinar and ductal cells
apoptosis than Sjögren’s syndrome338
0.005). However, the ratio of IgG1/total IgG increased from
38.3% to 46.8% (P < 0.01) while that of IgG4/total IgG
decreased from 34.9% to 16.7% (P < 0.005).
23 When ste-
roids were discontinued, swelling of the lacrimal and sali-
vary glands was observed, and the serum IgG4 levels
increased. It is thus necessary to continue prednisolone
administration at 5–10mg/day or combine it with an immu-
nosuppressant such as azathioprine.
Controversial points regarding Mikulicz’s disease
Prognosis and relationship with lymphoproliferative
diseases
The long-term prognosis of MD is unknown. Among SS
patients, the incidence of non-Hodgkin’s lymphoma is 43.8-
fold higher than the prevailing incidence in the general
population.
24 Sugai classiﬁed the severity of SS into three
stages: stage I, having only sicca symptoms; stage II, having
systemic organ involvement; and stage III, is complicated by
lymphoma. Glandular and extraglandular SS may thus be
considered as an early stage of lymphoma.
25  There have
also been reports on malignant transformation in MD.
26
Recently, Ihrler and Harrison speculated that the ﬁrst MD
case reported by Mikulicz in 1892 was MALT lymphoma
based on Mikulicz’s sketch of the specimen.
27  However,
none of the present cases exhibited IgH gene rearrange-
ment. It is necessary to continue the analysis of complicat-
ing lymphoma in MD as there is no data on its long-term
prognosis.
Interpretation of asymmetrical or individual lacrimal or
salivary gland swelling
In MD, enlargement of only the lacrimal or submandibular
glands sometimes leads to other glandular swelling.
Küttner’s tumor is chronic sclerosing sialadenitis that pre-
sents with asymmetrical ﬁrm swelling of the submandibular
glands.
28 It is predominantly found in males. The histologi-
cal characteristics of Küttner’s tumor are severe ﬁbrosis,
atrophic acinus, and mononuclear cell inﬁltration. Kitagawa
et al. analyzed 12 patients with Küttner’s tumor and found
that ﬁve cases were associated with sclerosing lesions in the
extrasalivary glandular tissues. Immunohistochemically, the
proportion of IgG4/IgG-positive plasmacytes was more
than 45% in Küttner’s tumor, while it was less than 5% in
SS.
29 We experienced a case of Küttner’s tumor presenting
with enlargement of only the right submandibular gland.
We did not evaluate the gland by immunostaining but found
elevated concentrations of serum IgG4 (33.1%). We also
experienced a case of chronic dacryadenitis presenting with
bilateral swelling of only the lacrimal glands. This case also
exhibited elevated concentrations of serum IgG4 (26.0%)
and prominent inﬁltration of IgG4-bearing plasma cells into
the glands. It is difﬁcult to assess whether Küttner’s tumor
and chronic dacryadenitis will develop in MD or whether
these differ substantially from MD. We cannot resolve this
problem at this point because the opinions of otorhinol-
aryngologists, ophthalmologists, and pathologists must be
considered. However, we have the impression that some of
the pathogenic features diagnosed in Küttner’s tumor or
chronic dacryadenitis are the same as those of MD. Thus,
we must also analyze and resolve the relationships between
MD and other diseases.
We regard symmetrical glandular swelling to be an indis-
pensable characteristic for diagnosing MD. We use the
name MD out of respect for the ﬁrst reporter of this condi-
tion – Johann von Mikulicz-Radecki. When it is proved that
Küttner’s tumor and chronic dacryadenitis are identical to
MD, we will call them by another common name. It is
possible that bilateral glandular swelling occurs in SS; how-
ever, it usually disappears within a few weeks without any
treatment. Persistence of the condition for a period of more
than 3 months is very rare.
b a
Fig. 2a,b. Specimens of labial salivary glands in patients with
Mikulicz’s disease (MD) and Sjögren’s syndrome (anti-IgG4 mono-
clonal antibody staining, magniﬁed 1:200). a  Mikulicz’s disease, b
Sjögren’s syndrome. The MD specimen exhibits abundant inﬁltration
of plasmacytes with IgG4339
Relationships with other IgG4-related diseases,
particularly autoimmune pancreatitis
Autoimmune pancreatitis is an IgG4-related disease. It
also exhibits hypergammaglobulinemia, particularly with
regard to IgG4, and severe inﬁltration of IgG4-positive
plasmacytes into the pancreas.
30,31 Autoimmune pancreatitis
was proposed by Yoshida et al. in 1995
32 because it was
presumed that autoimmunity was a part of the mechanism
of idiopathic chronic pancreatitis. The diagnostic criteria for
AIP were designed by the Japan Pancreas Society.
33,34
Obstructive jaundice with narrowing at the lower parts
of the common bile duct and impaired glucose tolerance
due to pancreatic dysfunction are the clinical characteristics
of AIP. Autoimmune pancreatitis patients are predomi-
nantly males with the male to female ratio reported to be
2–5 in Japan
33–36 and 2 in Europe.
37 The mean age at diagno-
sis is over 55 years.
35,36 Autoimmune pancreatitis patients
generally show serum hypergammaglobulinemia and in-
creased IgG levels as well as the presence of antibodies such
as antinuclear antibodies and rheumatoid factor. Computed
tomography or ultrasonography typically reveals a diffusely
enlarged pancreas, and endoscopic retrograde cholan-
giopancreatography (ERCP) images show segmental or dif-
fuse narrowing of the main pancreatic duct. Steroid therapy
is usually effective for improving pancreatic swelling and
pancreatic endocrine and exocrine secretion.
38,39  These
characteristics are similar to those of MD, i.e., elevated
concentrations of serum IgG4, inﬁltration of IgG4-bearing
plasma cells into the glands, and recovery of secretion by
glucocorticoid treatment. Furthermore, AIP is sometimes
complicated by MD.
10,40 Thus, MD and AIP are considered
to be related. Nakamura et al. reported an AIP case in
which IgG4-positive mononuclear cell inﬁltration was ob-
served not only in the pancreas but also in the salivary gland
and kidney.
41 Other complications associated with MD and
AIP include autoimmune hypophysitis,
42 Riedel’s thyroidi-
tis,
43  interstitial pneumonia,
44,45  sclerosing cholangitis,
46,47
retroperitoneal ﬁbrosis
31,44,47,48  and interstitial tubular ne-
phritis.
10,41,49  In our analysis, the concentrations of serum
IgG4 tended to be proportional to the frequency of these
complications. It is possible that serum IgG4 concentrations
reﬂect disease activity in systemic IgG4-related plasmacytic
diseases, which include MD and AIP.
Conclusion
We discussed the differences between MD and SS, such as
the elevated concentrations of serum IgG4 and the promi-
nent inﬁltration of IgG4-bearing plasma cells into lacrimal
and salivary glands observed in MD. Rheumatologists
should initially administer corticosteroids to MD patients in
order to treat glandular swelling and improve exocrine and
endocrine secretions. However, further analysis of the
pathogenesis of MD at the cellular and molecular levels is
required. Based on the evidence presented here, MD
should be considered as a part of a larger concept, i.e.,
IgG4-related palasmacytic diseases.
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